

<b>Coding Policy Policy and Procedure</b>		
SUBJECT: Coding Policy 64.0 Opioid Treatment Programs for Medicare Advantage	DEPARTMENT: <b>Product</b>	
ORIGINAL EFFECTIVE DATE: 03/2020	DATE(S) REVIEWED/REVISED: 03/20, 01/22	
APPROVED BY: Coding Policy Review Committee	NUMBER: <b>MC 64.0</b>	PAGE: <b>1 of 3</b>

**SCOPE:**

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

**APPLIES TO:**

Medicare Advantage Plans

**POLICY:**

Company will allow payment for opioid treatment for Providence Medicare Advantage Plans members following CMS guidelines, including reimbursement methodology, eligibility criteria, etc., for the Opioid Treatment Program (OTP). The requirements for using these codes are listed in the code descriptions, including, but not limited to, services provided by OTPs who are enrolled in Medicare, successfully completed the certification and accreditation process and meet other requirements outlined in 42 CFR 8.

**PROCEDURE:**

OTP providers who are certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) and accredited by an independent, SAMHSA-approved accrediting body will use the following codes to report OTP services.

G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)

<b>Coding Policy Policy and Procedure</b>		
SUBJECT: Coding Policy 64.0 Opioid Treatment Programs for Medicare Advantage	DEPARTMENT: <b>Product</b>	
ORIGINAL EFFECTIVE DATE: 03/2020	DATE(S) REVIEWED/REVISED: 03/20, 01/22	
APPROVED BY: Coding Policy Review Committee	NUMBER: <b>MC 64.0</b>	PAGE: <b>2 of 3</b>

G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2074	Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2075	Medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2215	Take-home supply of nasal naloxone, 2-pack of 4mg per 0.1 mL nasal spray
G2216	Take-home supply of injectable naloxone
G1028	Take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 mL nasal spray

<b>Intensity Add-on Codes</b>	
<b>HCPCS Code</b>	<b>Descriptor</b>
G2076	Intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment by a program physician or a primary care physician, or an authorized healthcare professional under the supervision of a program physician or qualified personnel that includes preparation of a treatment plan that includes the patient's short-term goals and the tasks the patient must perform to complete the short-term goals; the patient's requirements for education, vocational rehabilitation, and employment; and the medical, psycho- social, economic, legal, or other supportive services that a patient needs, conducted by qualified personnel (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2077	Periodic assessment; assessing periodically by qualified personnel to determine the most appropriate combination of services and treatment (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

<b>Coding Policy Policy and Procedure</b>		
SUBJECT: Coding Policy 64.0 Opioid Treatment Programs for Medicare Advantage	DEPARTMENT: <b>Product</b>	
ORIGINAL EFFECTIVE DATE: 03/2020	DATE(S) REVIEWED/REVISED: 03/20, 01/22	
APPROVED BY: Coding Policy Review Committee	NUMBER: <b>MC 64.0</b>	PAGE: <b>3 of 3</b>

G2078	Take-home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2079	Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2080	Each additional 30 minutes of counseling in a week of medication assisted treatment, (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.

**REFERENCES:**

CMS Guidelines for Opioid Treatment Program